Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Compliance with NICE guidance on the use of anti-TNFalpha agents in ankylosing spondylitis: an east and west Midlands regional audit.

Rees F, Peffers G, Bell C, Obrenovic K, Sandhu R, Packham J, Erb N; West Midlands Regional STC and East Midlands Regional Audit Group..

Clin Med (Lond). 2012 Aug;12(4):324-7.

PMID:
22930875
2.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

3.

Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.

Zochling J, Braun J.

Expert Opin Pharmacother. 2006 May;7(7):869-83. Review.

PMID:
16634710
4.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
5.

Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H.

Ann Rheum Dis. 2002 Dec;61 Suppl 3:iii51-60. Review.

6.

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group..

Ann Rheum Dis. 2006 Mar;65(3):316-20. Epub 2005 Aug 11.

7.

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group..

Ann Rheum Dis. 2003 Sep;62(9):817-24. Review.

8.

Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.

De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E.

Drugs. 2004;64(24):2793-811. Review.

PMID:
15563249
9.

Etanercept: in ankylosing spondylitis.

McCormack PL, Wellington K.

BioDrugs. 2004;18(3):199-205; discussion 206. Review.

PMID:
15161337
10.

[Anti-TNF alfa therapy in ankylosing spondylitis].

Cravo AR, Tavares V, Da Silva JC.

Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18. Review. Portuguese.

Supplemental Content

Support Center